MAZE Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 81% planned / 19% discretionary
Largest single sale: $907.9K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO | Sell 10b5-1 | 9,705 | $26.22 | $254.5K | None left | |
| Coloma Jason V 2 fills | Chief Executive Officer | Sell | 11,411 | $26.01 | $296.8K | 27,491 −29.3% of holding | |
| Bernstein Harold 2 fills | President, R&D & CMO | Sell | 5,189 | $26.01 | $135.0K | 9,764 −34.7% of holding | |
| Dandekar Atul 2 fills | CSBO | Sell | 3,243 | $26.01 | $84.4K | 32,352 −9.1% of holding | |
| Courtney Phillips 2 fills | GC and Corp. Secretary | Sell | 2,012 | $26.01 | $52.3K | 7,029 −22.3% of holding | |
| Coloma Jason V 2 fills | Chief Executive Officer | Sell | 11,227 | $26.47 | $297.1K | 40,148 −21.9% of holding | |
| Bernstein Harold 2 fills | President, R&D & CMO | Sell | 5,106 | $26.47 | $135.1K | 15,519 −24.8% of holding | |
| Dandekar Atul 2 fills | CSBO | Sell | 3,191 | $26.47 | $84.5K | 35,950 −8.2% of holding | |
| Courtney Phillips 2 fills | GC and Corp. Secretary | Sell | 1,981 | $26.47 | $52.4K | 9,262 −17.6% of holding | |
| Bernstein Harold | President, R&D & CMO | Sell 10b5-1 | 16,141 | $26.36 | $425.5K | None left | |
| Dandekar Atul | CSBO | Sell 10b5-1 | 7,500 | $27.58 | $206.8K | 26,250 −22.2% of holding | |
| Bernstein Harold | President, R&D & CMO | Sell 10b5-1 | 16,142 | $27.61 | $445.6K | None left | |
| Coloma Jason V 4 fills | Chief Executive Officer | Sell 10b5-1 | 34,501 | $26.73 | $922.3K | 256,867 −11.8% of holding | |
| Dandekar Atul 2 fills | CSBO | Sell 10b5-1 | 7,500 | $27.34 | $205.0K | 26,650 −22% of holding | |
| Coloma Jason V 3 fills | Chief Executive Officer | Sell 10b5-1 | 34,501 | $29.98 | $1.0M | 288,768 −10.7% of holding | |
| Bernstein Harold 2 fills | President, R&D & CMO | Sell 10b5-1 | 14,609 | $29.90 | $436.9K | 1,200 −92.4% of holding | |
| Dandekar Atul | CSBO | Sell 10b5-1 | 7,500 | $28.02 | $210.2K | 26,250 −22.2% of holding | |
| Coloma Jason V | Chief Executive Officer | Sell 10b5-1 | 23,865 | $26.05 | $621.7K | 319,079 −7% of holding | |
| Coloma Jason V 2 fills | Chief Executive Officer | Sell 10b5-1 | 3,993 | $26.00 | $103.8K | 342,944 −1.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.